Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Clark, D. J.
Right arrow Articles by Lipworth, B. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Clark, D. J.
Right arrow Articles by Lipworth, B. J.
(Chest. 1997;112:1248-1252.)
© 1997 American College of Chest Physicians

Evaluation of Corticotropin Releasing Factor Stimulation and Basal Markers of Hypothalamic-Pituitary-Adrenal Axis Suppression in Asthmatic Patients

D. J. Clark MB, ChB1 and Brian J. Lipworth MD1

1 From the Department of Clinical Pharmacology, Ninewells Hospital and Medical School, University of Dundee, Dundee, Scotland

Purpose: The aim of our study was to compare basal unstimulated levels of plasma cortisol and adrenocorticotropic hormone (ACTH) with stimulated levels produced by the corticotropin releasing factor (CRF) test in asthmatics taking high-dose inhaled steroid therapy. In theory, the CRF test would appear to be a suitable replacement for tetracosactrin (cosyntropin) (synthetic ACTH) as a test of hypothalamic-pituitary-adrenal (HPA) axis suppression.

Patients and Methods: Ten patients with stable asthma and a mean age of 28.8 years, FEV1 of 88.9% predicted, and forced expiratory flow between 25% and 75% of FVC of 57.0% predicted, were studied in a double-blind placebo-controlled crossover design comparing 4 days with budesonide, 1,000 µg bid, and placebo. Each dose was given at 8 AM and 10 PM for 4 days by metered-dose inhaler. Measurements were made at steady-state of basal 8 AM plasma cortisol and ACTH 10 h after the eighth dose, and CRF test (100-µg IV bolus) was then performed.

Results: The results for 8 AM plasma cortisol (nmol/L, means and 95% confidence interval [CI] for difference) showed that budesonide produced significant suppression compared with placebo: budesonide (284.1) vs placebo (360.9) (95% CI, 9.3 to 144.3). Suppression also occurred for peak plasma cortisol in response to CRF: budesonide (375.9) vs placebo (470.2) (95% CI, 27.0 to 161.6). ACTH (ng/L, means and 95% CI for difference) demonstrated a similar nonsignificant trend to cortisol, with suppression in both basal and stimulated forms: 8 AM ACTH, budesonide (36.6) vs placebo (42.2) (95% CI, minus2.6 to 13.8); CRF peak response, budesonide (49.9) vs placebo (62.8) (95% CI, minus3.6 to 29.5).

Conclusion: In asthmatic patients receiving inhaled budesonide, 1,000 µg bid, the suppression of basal unstimulated 8 AM plasma cortisol was mirrored by the suppression of the CRF stimulation response. These results highlight the point that when basal 8 AM plasma cortisol levels are suppressed, a comparable degree of dynamic impairment of HPA axis response is also likely to be found with physiologic testing.

Key Words: asthma • basal markers • corticotropin releasing factor • hypothalamic-pituitary-adrenal axis suppression • inhaled budesonide

Submitted on June 6, 1996
Accepted on April 22, 1997




This article has been cited by other articles:


Home page
 EndocrinologyHome page
G. Abraham, J. Gottschalk, and F. R. Ungemach
Evidence for Ototopical Glucocorticoid-Induced Decrease in Hypothalamic-Pituitary-Adrenal Axis Response and Liver Function
Endocrinology, July 1, 2005; 146(7): 3163 - 3171.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
D. K. C. Lee, T. C. Fardon, C. E. Bates, K. Haggart, L. C. McFarlane, and B. J. Lipworth
Airway and Systemic Effects of Hydrofluoroalkane Formulations of High-Dose Ciclesonide and Fluticasone in Moderate Persistent Asthma
Chest, March 1, 2005; 127(3): 851 - 860.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
C. d. F. Cunha, I. N. Silva, and F. L. Finch
Early Adrenocortical Recovery after Glucocorticoid Therapy in Children with Leukemia
J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 2797 - 2802.
[Abstract] [Full Text] [PDF]

Home page
 Psychosom. Med.Home page
A. Buske-Kirschbaum, K. von Auer, S. Krieger, S. Weis, W. Rauh, and D. Hellhammer
Blunted Cortisol Responses to Psychosocial Stress in Asthmatic Children: A General Feature of Atopic Disease?
Psychosom Med, September 1, 2003; 65(5): 806 - 810.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
L Pescollderungg, G Radetti, E Gottardi, D G Peroni, A Pietrobelli, and A L Boner
Systemic activity of inhaled corticosteroid treatment in asthmatic children: corticotrophin releasing hormone test
Thorax, March 1, 2003; 58(3): 227 - 230.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Buske-Kirschbaum, A. Geiben, H. Hollig, E. Morschhauser, and D. Hellhammer
Altered Responsiveness of the Hypothalamus-Pituitary-Adrenal Axis and the Sympathetic Adrenomedullary System to Stress in Patients with Atopic Dermatitis
J. Clin. Endocrinol. Metab., September 1, 2002; 87(9): 4245 - 4251.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. M. Wilson, L. C. McFarlane, and B. J. Lipworth
Effects of Low and High Doses of Inhaled Flunisolide and Triamcinolone Acetonide on Basal and Dynamic Measures of Adrenocortical Activity in Healthy Volunteers
J. Clin. Endocrinol. Metab., March 1, 1998; 83(3): 922 - 925.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the American College of Chest Physicians.